Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 7;128:104424.
doi: 10.1016/j.jcv.2020.104424. Online ahead of print.

SARS-CoV-2 and Enhancing Antibodies

Affiliations
Free PMC article

SARS-CoV-2 and Enhancing Antibodies

Joachim Denner. J Clin Virol. .
Free PMC article

Similar articles

See all similar articles

References

    1. Killerby M.E., Biggs H.M., Haynes A., Dahl R.M., Mustaquim D., Gerber S.I., Watson J.T. Human coronavirus circulation in the United States 2014-2017. J Clin Virol. 2018;101:52–56. - PMC - PubMed
    1. Wang Q., Zhang L., Kuwahara K., Li L., Liu Z., Li T., Zhu H., Liu J., Xu Y., Xie J., Morioka H., Sakaguchi N., Qin C., Liu G. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis. 2016;2(5):361–376. - PMC - PubMed
    1. Wan Y., Shang J., Sun S. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020;94(5):e02015–19. - PMC - PubMed
    1. Rey F.A., Stiasny K., Vaney M.C., Dellarole M., Heinz F.X. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2018;19(2):206–224. - PMC - PubMed
    1. Shen C., Wang Z., Zhao F. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 doi: 10.1001/jama.2020.4783. Mar 27. - DOI
Feedback